Oculis Holding AG has appointed Katie Kazem to the position of Chief Legal Officer, bringing extensive expertise in corporate governance and securities matters within the life sciences sector. Kazem's appointment reflects the company's strategic focus on strengthening its executive leadership as it navigates an increasingly complex regulatory and commercial environment.
The timing of Kazem's arrival coincides with a critical phase in Oculis' clinical development strategy. The company is advancing three late-stage therapeutic candidates, including Privosegtor, which is currently in registrational trials, and OCS-01 eye drops, for which Phase 3 trial results are anticipated in the second quarter of 2026. These milestones represent key inflection points that typically demand robust legal and compliance infrastructure.
Kazem's background spanning more than 15 years in life sciences law positions her to oversee regulatory submissions, corporate transactions, and shareholder matters as Oculis progresses toward potential regulatory approvals and commercialization.